European Academy of Dermatology & Venerology (EADV), 2024

Bimekizumab treatment in plaque psoriasis resulted in a rapid and deep normalisation of molecular signatures associated with PASI sub-components, that preceded clinical skin clearance

Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT

Rapid joint and skin responses were observed in patients with active psoriatic arthritis treated with bimekizumab: A pooled analysis from two phase 3 studies

Bimekizumab treatment history and quality of life outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE

Bimekizumab treatment history and clinical outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE

Bimekizumab in routine clinical practice: Baseline characteristics and treatment history of patients with moderate to severe plaque psoriasis from the second interim analysis of ELEVATE

Bimekizumab: Exploring the fast onset, high level, and durability of clinical and molecular responses in patients with psoriatic disease – Design and rationale behind the exploratory, multicentre, open-label phase 3b BE UNIQUE study

Bimekizumab PASI response levels in Week 16 PASI responders with moderate to severe plaque psoriasis through 4 years: Results from BE BRIGHT

Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response

Bimekizumab impact on clinical markers of liver fibrosis and key liver parameters in patients with moderate to severe plaque psoriasis: Long-term pooled data from BE BRIGHT

Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods

Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT

Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT

Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicentre, randomised, open-label studies

Bimekizumab maintenance of response from the end of pivotal trials through 4 years: Results in patients with moderate to severe plaque psoriasis from BE BRIGHT

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Bimekizumab: Network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients

Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II

Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II

Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials

Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies